Solid Tumor Testing Market in the US 2016-2020

February 24, 2016
This region-based market research report segments the solid tumor testing market in the US by technology (genetic testing and conventional testing) and by cancer type (breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and others). The key vendors analyzed in this market research are Abbott Molecular, Agilent Technologies (Dako), Beckman Coulter, and Roche Diagnostics.

Overview of the solid tumor testing market in the US

Solid tumor screening or testing is a medical procedure that helps in the early detection of cancer by enabling effective treatment measures to avoid the spread of cancerous cells throughout the body. The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Due to the implementation of the healthcare reform in the US, the number of citizens covered by insurance has increased, and the government has also introduced many reimbursement policies for sample testing. The introduction of such effective reimbursement policies will propel the adoption of these tests in terms of the volume of the insured patients. Technavio’s market research analyst has estimated the solid tumor testing market in the US to grow at a CAGR of over 11% by 2020.

The rising use of bench-top mass spectrometer will be the key driver for the growth of this market. Mass spectrometry is an advanced instrumentation technology, which plays a vital role in cancer testing because it relates to an increase in the throughput and coverage of complex proteome/genome analysis. A major advantage of this technology is its ability to give accurate results with a minimal quantity of sample. During the forecast period, it is anticipated that this technology will produce breakthrough advances in diagnosis by the characterization of macromolecules to understand a host of cancers that are difficult to screen and diagnose.

Technological segmentation of the solid tumor testing market in the US

  • Genetic testing
  • Conventional testing

In this segmentation analysis, the analysts have estimated the conventional testing technology segment to account for almost 59% of the overall market share by 2020. Conventional testing for solid tumors primarily includes mutation tests that study mutation analysis or genetic alterations in cancerous cells. The commonly used conventional tests are immunoassay-based tests that have been performed on systems such as UniCel DxL 600 and UniCel DxL 800.

Segmentation by cancer type and analysis of the solid tumor testing market in the US

  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer

This market study identifies the lung cancer segment to be the largest market segment during the forecast period. Lung cancer is usually caused by genetic factors, and exposure to air pollution and asbestos. It is a prime cause of cancer-related deaths globally and occurs in both genders. A major advance in the lung cancer detection technology is the discovery of tyrosine kinase inhibitors, which is a lung cancer biomarker. The mutations occurring in tyrosine kinase inhibitors help determine lung cancer by fluorescent in situ hybridization (FISH) technique.

Competitive landscape and key vendors

The solid tumor testing market in the US is intensely competitive because of the presence of many small and medium-sized providers in the US. Vendors offer few products in the market and are focusing on expanding their market penetration by launching innovative products, such as POC cancer testing kits, in the market. The large-scale acquisition of small and medium-sized manufacturers by large corporations will help the prominent vendors to expand their market shares.

Top vendors in the market are -

  • Abbott Molecular
  • Agilent Technologies (Dako)
  • Beckman Coulter
  • Roche Diagnostics

Other prominent vendors in the market are 20/20 GeneSystems, Adaptive Biotechnologies, Advanced Cell Diagnostics, Affymetrix, Agena Bioscience, Ambry Genetics, ApoCell, Avant Diagnostics, Biological Dynamics, Boditech Med, Becton, Dickinson and Company (BD), Biocare Medical, Bio-Rad Laboratories, Castle Biosciences, CDx Diagnostics, Celerus Diagnostics, Cancer Genetics, Caris Life Sciences, Clarient Diagnostic Services, DiaTech Oncology, Enzo Biochem, Epic Sciences, EDP Biotech, Eutropics Pharmaceuticals, Fujirebio Diagnostics, Genalyte, Hologic, Janssen Diagnostics, Myriad Genetics, Omnyx, OxfordGene Technology, Oncospire Genomics, OncoCyte, OvaGene Oncology, Pathway Genomics, Quest Diagnostics, QIAGEN, RiboMed Biotechnologies, Sequenom, Siemens Healthcare Diagnostics, Thermo Fisher Scientific, Tosoh Bioscience, and TrimGen.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the solid tumor testing market in the US?
  • What are the key market trends impacting the growth of the solid tumor testing market in the US?
  • What are the challenges to market growth?
  • Who are the key vendors in the solid tumor testing market in the US?
  • What are the market opportunities and threats faced by the vendors in the solid tumor testing market in the US?
  • Trending factors influencing the market shares of the US.
  • What are the key outcomes of the five forces analysis of the solid tumor testing market in the US?

Technavio also offers customization on reports based on specific client requirement.

Related reports